Leurubicin

CAS No. 70774-25-3

Leurubicin( —— )

Catalog No. M34094 CAS No. 70774-25-3

Leurubicin (N-Leucyldoxorubicin) is a potential Top II inhibitor for the study of bacterial infections .

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
2MG 445 Get Quote
500MG Get Quote Get Quote
1G Get Quote Get Quote

Biological Information

  • Product Name
    Leurubicin
  • Note
    Research use only, not for human use.
  • Brief Description
    Leurubicin (N-Leucyldoxorubicin) is a potential Top II inhibitor for the study of bacterial infections .
  • Description
    Leurubicin (N-Leucyldoxorubicin) is a potential Top II inhibitor for the study of bacterial infections .
  • In Vitro
    ——
  • In Vivo
    ——
  • Synonyms
    ——
  • Pathway
    Cell Cycle/DNA Damage
  • Target
    Topoisomerase
  • Recptor
    Topoisomerase
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    70774-25-3
  • Formula Weight
    656.68
  • Molecular Formula
    C33H40N2O12
  • Purity
    >98% (HPLC)
  • Solubility
    ——
  • SMILES
    OC=1C2=C([C@@H](O[C@H]3C[C@H](NC([C@H](CC(C)C)N)=O)[C@H](O)[C@H](C)O3)C[C@@](C(CO)=O)(O)C2)C(O)=C4C1C(=O)C=5C(C4=O)=C(OC)C=CC5
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

molnova catalog
related products
  • Daniquidone

    Daniquidone (Batracylin) is a potent dual inhibitor of DNA topoisomerase I and DNA topoisomerase II with cytotoxic and antiproliferative activity that induces DNA fragmentation for the study of neoplasms, immune disorders, and lymphatic disorders.

  • Genz-644282

    Genz-644282 a novel non-camptothecin topoisomerase I inhibitor for cancer treatment.

  • N-Acetyl-D-Glucosami...

    N-acetyl-D-Glucosamine (GlcNAc) is a monosaccharide derivative of glucose. It is released by the action of O-GlcNAcase, in mammalian systems from proteins that have been post-translationally modified with O-GlcNAc.